Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8IV38
UPID:
ANKY2_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IV38; A4D124; Q659G1; Q96BL3
Background:
Ankyrin repeat and MYND domain-containing protein 2 plays a crucial role in cellular processes, potentially involved in the trafficking of signaling proteins to the cilia. This protein's unique structure, characterized by ankyrin repeats and MYND domains, suggests a specific function in cellular signaling pathways.
Therapeutic significance:
Understanding the role of Ankyrin repeat and MYND domain-containing protein 2 could open doors to potential therapeutic strategies. Its involvement in signaling protein trafficking highlights its importance in cellular function and disease mechanisms.